Full-Time

Director of Quality Assurance

Clinical

Caribou Biosciences

Caribou Biosciences

51-200 employees

Develops allogeneic CRISPR CAR-T therapies

Compensation Overview

$220k - $235k/yr

+ Bonus + Equity

No H1B Sponsorship

Berkeley, CA, USA

Hybrid

Travel up to 25-30% based on business needs.

US Citizenship, US Top Secret Clearance, Canada Citizenship, Canada Top Secret Clearance, UK Citizenship, UK Top Secret Clearance Required

Bachelor's, Master's

Category
QA & Testing (1)
Required Skills
Risk Management
Google Cloud Platform

Get referred to Caribou Biosciences

See people who can refer or advise you

Requirements
  • Undergraduate or graduate degree in Biological Sciences, Chemistry, or related Science discipline with at least 15 years of experience in clinical quality assurance (GCP, GLP and PV) in cell & gene therapy/biotechnology and/or pharmaceutical industry.
  • Experience working in biologics is strongly preferred.
  • Subject Matter Expert (SME) working knowledge on current interpretation/implementation of United States Code of Federal Regulations, ICH Guidelines and other local government regulatory requirements governing clinical research.
  • Proven track record in developing and implementing quality systems and processes in a clinical setting.
  • Expertise in creating and executing audit plans outlining all service providers (vendor) audits, clinical investigator site audits, CSV audits and process audits.
  • Advanced knowledge of Quality Assurance principles, concepts, industry practices, and standards.
  • Prior GLP experience with quality oversight and auditing studies/vendors (preferred).
  • Excellent verbal and written communication skills, ability to lead cross-functional teams and independently prioritize work, manage multiple projects while maintaining quality and being an advocate for quality and regulatory compliance.
  • The position requires a highly diplomatic, and tactful individual with excellent critical reasoning skills.
  • Conscientiously detail-oriented and organized, impeccable attention to data review.
  • Ability to deal with ambiguity and use expertise and skills to contribute to the development of company objectives and principles, and to achieve goals in creative and effective ways.
  • Must be flexible and able to multi-task, prioritize, meet deadlines in a fast-paced environment, and be adaptable to setbacks.
  • Detail-oriented mindset with a proactive approach to problem-solving and decision-making.
  • Certification in quality assurance (e.g., Certified Quality Auditor) and/or GCP (e.g., Certified Clinical Research Professional) is desirable.
  • Ability to travel up to 25-30% based on business needs.
Responsibilities
  • Compliance Oversight: Ensure that all clinical trial activities comply with guidelines and international regulations (e.g., ICH-GCP and ICH-PV), and applicable laws.
  • Documentation Review: Conduct thorough reviews of study-related documentation, including protocols, investigator brochures, informed consent forms, and CSRs, to verify compliance with GCP requirements.
  • Provide Clinical Quality Assurance (GCP) strategic and technical leadership and Subject Matter Expertise (SME) to clinical study teams; Partner with the teams to effect appropriate and timely documentation of quality event management, including CAPA plans in support of product pipeline.
  • Plan and oversee activities in support of regulatory submissions and inspections; Lead GCP Inspection Readiness efforts, ensure implementation and prepare internal and external teams for Pre-Approval Inspections (PAI).
  • Implement, monitor, and promote best practices of all Quality Assurance Systems to ensure compliance with relevant FDA, EU and ROW regulations/directives/requirements and ICH guidelines.
  • Quality Management System (QMS): Maintain and enhance Caribou’s QMS by implementing processes and procedures that ensure consistent adherence to GCP, GLP and PV standards throughout the clinical trial lifecycle.
  • Develop and implement the appropriate suite of Standard Operating Procedures (SOPs), quality manuals, policies, and other related quality documents. Ensure that these systems are effectively communicated, understood, and followed by relevant stakeholders.
  • Create and implement clinical quality risk management strategies to identify, assess, and mitigate risks associated with clinical development and operations. This involves conducting risk assessments, developing risk mitigation plans, and overseeing their implementation.
  • Build training and approve curricula based on the key elements of the Quality System; Provide leadership and oversight for training programs related to pre-clinical, clinical and PV. Ensure that employees and relevant stakeholders receive appropriate training on quality standards, regulations, and procedures.
  • Establish and monitor quality metrics and key performance indicators for the effectiveness of pre-clinical, clinical, and PV quality assurance activities. Prepare routine reports and presentations for senior/executive management review highlighting quality performance, trends, and areas for improvement. Assist with tracking compliance audit trends and present to management.
  • Collaborate with cross-functional teams, including pre-clinical, clinical operations, regulatory affairs, pharmacovigilance, and other relevant departments, to ensure alignment and integration of quality assurance activities. Build and maintain effective relationships with internal and external stakeholders, including regulatory agencies and service providers.
  • Perform internal and external audits to ensure stakeholder system compliance with existing policies and procedures, and requirements, standards, and guidelines.
  • Lead and/or manage additional Quality Assurance (GxP) initiatives or programs as business needs evolve.
Desired Qualifications
  • Certification in quality assurance (e.g., Certified Quality Auditor) and/or GCP (e.g., Certified Clinical Research Professional) is desirable.
  • Travel availability up to 25-30%.

Caribou Biosciences develops allogeneic CAR-T cell therapies using a CRISPR-based chRDNA platform (Cas9 and Cas12a) to create precise genome edits. Its lead approach centers on off-the-shelf, armored CAR-T cells designed to persist longer and resist exhaustion, including PD-1 knockout, enabling rapid access for patients. The company advances wholly-owned programs and collaborates with pharma partners, such as AbbVie, to push its therapies through clinical development. Its goal is to bring regulated, off-the-shelf CAR-T therapies to patients with hematologic cancers and autoimmune diseases and to reach commercialization, supported by funding through at least 2027.

Company Size

51-200

Company Stage

IPO

Headquarters

Berkeley, California

Founded

2011

Get referred to Caribou Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 7, 2026 FDA alignment on ANTLER-3 de-risks vispa-cel’s path to pivotal testing.
  • March 31, 2026 FDA RMAT for CB-011 validates the multiple myeloma program.
  • Caribou reported $118.6 million cash on March 31, 2026 and runway into 2H 2027.

What critics are saying

  • May 2026 ANTLER-3 alignment still leaves Caribou dependent on a single pivotal readout.
  • CB-011 and vispa-cel must beat autologous CAR-Ts and emerging bispecifics by 2027.
  • A failed financing for the pivotal vispa-cel program would force another dilution or shutdown.

What makes Caribou Biosciences unique

  • Caribou’s chRDNA platform and PD-1 knockout design distinguish vispa-cel from standard allogeneic CAR-Ts.
  • Founded by Jennifer Doudna and Rachel Haurwitz, Caribou still markets CRISPR credibility to investors.
  • Vispa-cel and CB-011 target off-the-shelf access, faster dosing, and broader hospital scalability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Tuition Reimbursement

Generous paid vacation time

Comprehensive compensation package

ESPP

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-6%
Provisioner Online
Aug 1st, 2026
Gene editing: the next essential tool for agriculture.

Gene editing: the next essential tool for agriculture. August 1, 2026 Agriculture has always evolved through better tools. From selective breeding and artificial insemination to precision nutrition and modern biosecurity, producers have consistently adopted innovations that improve animal health, efficiency and long-term sustainability. Now, gene editing is emerging as the industry's next major advancement - and unlike many tools before it, it's already influencing daily life far beyond the farm. For swine producers awaiting access to PIC's porcine reproductive and respiratory syndrome (PRRS)-resistant pig, that broader context matters. Gene editing is no longer just a concept discussed in labs. It's already being used to improve food production systems, reshape the grocery aisle and deliver transformational therapies for devastating diseases like cancer. Improving food production efficiency and quality. "Five or 10 years ago, having gene-edited food products on shelves was more of a vision," says Ryan Bartlett, PhD, Chief Technology and Commercial Officer at Pairwise. "Today, these products are being produced and are on grocery store shelves." Pairwise, an agricultural technology company focused on CRISPR gene editing applications in plants, partners with organizations including Bayer, Corteva and Sun World to improve production efficiency in row crops and consumer-facing foods. The vision is simple: use gene editing to solve practical problems faster than traditional breeding alone can. "Traditional breeding could potentially get us there one day, but it may take 50 years," says Bartlett. "Gene editing allows us to make meaningful improvements on a much faster timeline. And time is the limiting factor in everything we do as farmers." That accelerated timeline matters in agriculture, where producers face constant pressure to improve efficiency, sustainability and food quality. One example is the seedless blackberry, which Pairwise helped develop after consumers repeatedly shared the same frustration: they loved the fruit's flavor and nutritional value but disliked the seeds. "Convenience drives consumption," says Bartlett. "Now families can give their kids a nutritious choice without the nuisance of seeds." The same technology is also being used to address global food system challenges. Pairwise is also working to develop more compact yam varieties for use in African production systems, where improved efficiency could help address nutritional deficits in regions where yams are a staple. Transforming human healthcare outcomes. Outside of agriculture, gene editing is transforming human medicine. "In the U.S., patients now have access to approved gene therapies that treat inherited diseases, including certain forms of blindness, hemophilia and several types of blood cancer," says Rachel Haurwitz, Ph.D., President and CEO of Caribou Biosciences. "More recently, we've seen the first CRISPR-based gene-edited cell therapy approved for sickle cell anemia." Caribou Biosciences, Inc., founded by CRISPR pioneers including Nobel Prize winner Jennifer Doudna, is using gene editing technology to develop therapies for blood cancer. Caribou's own gene-edited CAR-T cell therapies are showing promising results in patients who had exhausted other treatment options, with some patients remaining cancer-free years after a single treatment. For Haurwitz, those outcomes reinforce the broader potential of gene editing across industries. "This is not a single-use technology," she says. "It is a platform that can address challenges across human health, animal health, agriculture and many other fields." Tackling the swine industry's challenge: PRRS. For swine producers, one of those challenges is PRRS. Traditional biosecurity, vaccination and management strategies remain essential, but PRRS continues to pose a threat due to its ability to mutate and spread aggressively. Haurwitz sees PIC's work as an example of gene editing solving a highly targeted, real-world problem. "By making a specific change to a gene involved in how the PRRS virus enters cells, PIC has created pigs that are resistant to the disease without introducing foreign DNA," she says. "That kind of precise, intentional change is exactly what makes CRISPR genome editing so powerful." Industry leaders believe gene editing will ultimately become another practical tool within agriculture - not a replacement for good management or breeding practices. In addition to solving operational problems for producers, gene editing represents an opportunity to meet consumer demands at the same time. The technology is a pathway for achieving reductions in antibiotic use, improved convenience, increased sustainability, enhanced nutrition and more - features that consumers are increasingly seeking out and endorsing with their purchase decisions. With gene editing and gene therapies also leading to monumental solutions for devastating human diseases, consumers are growing increasingly familiar with gene editing and the benefits it can provide. "I think gene editing is going to become an integrated platform across all segments of agriculture," says Bartlett. "If we do this right, it's going to be pretty seamless." The future of gene editing does not represent a technological revolution, but rather a continuation of the promise producers have always made: adopting better tools to care for animals, improve productivity and build a more sustainable future.

Investing News Network
May 27th, 2026
Caribou Biosciences to participate in the 2026 Jefferies Global Healthcare Conference.

Caribou Biosciences to participate in the 2026 Jefferies Global Healthcare Conference. May 27, 2026 Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35pm ET in New York. About Caribou Biosciences, Inc. Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou's chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit www.cariboubio.com. Caribou Biosciences, Inc. contact: Peggy Vorwald, PhD [email protected] [email protected] 08 April 2022

StockTitan
May 13th, 2026
Caribou Biosciences to participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference.

Caribou Biosciences to participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference. Rhea-AI Impact Rhea-AI Sentiment Rhea-AI summary. Caribou Biosciences (Nasdaq: CRBU) announced that its management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026 at 12:30 p.m. ET in New York. A live webcast and replay will be available for at least 30 days on the Events page of Caribou's website. AI-generated analysis. Not financial advice. Key figures. Licensing & other revenue: $2.4M R&D expenses: $20.6M G&A expenses: $8.1M +5 more Market reality check. Price: $2.04 Vol: Volume 1,700,022 is sligh... normal vol Peers on argus. Sector peers showed mixed moves with both gains and losses, and only one momentu... Historical context. 5 past events · Latest: May 12 (Positive) Pattern 5 events Market pulse summary. This announcement adds another investor-relations touchpoint as Caribou Biosciences participates in... Key terms. crispr, genome-editing AI-generated analysis. Not financial advice. 05/13/2026 - 01:05 PM BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou's management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 12:30pm ET in New York, New York. About Caribou Biosciences, Inc. Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou's chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit www.cariboubio.com. Caribou Biosciences, Inc. contact: Peggy Vorwald, PhD [email protected] [email protected] Faq. When will Caribou Biosciences (CRBU) present at the H.C. Wainwright 4th Annual BioConnect Investor Conference? Caribou Biosciences will participate in a fireside chat on May 19, 2026 at 12:30 p.m. ET. According to Caribou, the event will take place in New York, New York. How can investors access the Caribou Biosciences (CRBU) BioConnect conference webcast? Investors can access the webcast via the Events page on Caribou's website. According to Caribou, the webcast link and additional event information will be provided there. Will a replay of the Caribou Biosciences (CRBU) BioConnect fireside chat be available? Yes, a replay of the fireside chat will be available on Caribou's website. According to Caribou, webcasts will remain accessible for at least 30 days after the event. What is the focus of Caribou Biosciences (CRBU) at the H.C. Wainwright 4th Annual BioConnect Investor Conference? Caribou Biosciences' management will join a fireside chat with investors at the conference. According to Caribou, the appearance offers an opportunity to discuss its clinical-stage CRISPR genome-editing programs. Where is the H.C. Wainwright 4th Annual BioConnect Investor Conference featuring Caribou Biosciences (CRBU) being held? The conference session featuring Caribou Biosciences will be held in New York, New York. According to Caribou, the fireside chat is scheduled there on May 19, 2026.

TipRanks
Jan 2nd, 2025
Caribou Biosciences Appoints New CFO Amid Clinical Advancements

Caribou Biosciences announced the appointment of Sri Ryali as Chief Financial Officer, effective January 2, 2025.

TechBullion
Sep 10th, 2024
Vir Biotechnology Names Jason O'Byrne as Chief Financial Officer

Mr. O'Byrne joins Vir from Caribou Biosciences, Inc., where he served as CFO, leading the finance, investor relations, corporate communications, IT, procurement, and operations functions as the company advanced its pipeline of clinical-stage cell therapies in oncology and autoimmune disease.